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Edible fruits are inexpensive biofactories for human health promoting molecules that 
can be ingested as crude extracts or partially purified formulations. We show here the 
production of a model human antibody for passive protection against the enteric pathogen 
rotavirus in transgenically labelled tomato fruits. Transgenic tomato plants expressing a 
recombinant human immunoglobulin A (hIgA_2A1) selected against the VP8* peptide of 
rotavirus SA11 strain were obtained. The amount of hIgA_2A1 protein reached 3.6 ± 0.8% of 
the total soluble protein (TSP) in the fruit of the transformed plants. Minimally-processed fruit-
derived products suitable for oral intake showed anti-VP8* binding activity and strongly 
inhibited virus infection in an in vitro virus neutralization assay. In order to make tomatoes 
expressing hIgA_2A1 easily distinguishable from wild type tomatoes, lines expressing 
hIgA_2A1 transgenes were sexually crossed with a transgenic tomato line expressing the genes 
encoding Antirrhinum majus Rosea1 and Delila transcription factors, which confer purple 
colour to the fruit. Consequently, transgenically labelled purple tomato fruits expressing 
hIgA_2A1   have been developed. The resulting purple-coloured extracts from these fruits 
contain high levels of recombinant anti-rotavirus neutralizing human IgA in combination with 
increased amounts of health-promoting anthocyanins.  
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Introduction 
Fleshy fruit have been traditionally exploited as natural biofactories for orally-active, 
health-promoting metabolites (Cipollini and Levey, 1997). Recently, they have also been 
envisioned as an excellent vehicle for nutritional enhancement and considerable efforts have 
been made to enrich their content of indigenous and/or exotic human health-promoting 
compounds such as carotenoids, folate, flavonols or anthocyanins through molecular breeding 
and metabolic engineering (Apel and Bock, 2009; Bovy et al., 2002; Bovy et al., 2007; Butelli 
et al., 2008; Davuluri et al., 2005; Giuliano et al., 2008).  Unlike other plant-derived products, 
edible fruit and their derivatives are considered safe and palatable for human consumption in 
unheated, minimally processed forms, and their content of anti-nutrients and toxic compounds 
sharply decreases upon ripening. This feature makes edible fruits ideal biofactories for exotic 
heat-labile compounds with mucosal activity such as health-promoting metabolites and mucosal 
active proteins like oral vaccines, immune modulators, biocides and/or antibodies for artificial 
passive immunotherapy.  
Transgenic crops have been proposed as advantageous platforms for recombinant 
antibody production due to their productivity, scalability, and the low risk of contamination with 
mammalian pathogens (De Muynck et al., 2010). The technical feasibility of an artificial passive 
immunization approach based on a plant-made antibody was first demonstrated by the 
pioneering work of Ma and colleagues who expressed in tobacco a hybrid murine/human 
secretory immunoglobulin G/A  (Guy´s 13 sIgG/A) which is effective against tooth decay (Ma 
et al., 1995; Ma et al., 1994; Ma et al., 1998). The Guy´s 13 monoclonal antibody produced in 
tobacco provided effective protection against Streptococcus mutans infections in healthy 
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volunteers. The technology to express Guy's 13 sIgG-A in plants was licensed by Planet 
Biotechnology Inc (USA). This was the first plant-made antibody that was evaluated in phase I 
and II clinical trials (Weintraub et al., 2005) as CaroRx
TM
. In the United States, CaroRx™ is an 
Investigational New Drug and in the European Union, it is a registered Medical Device. More 
recently, the anti-HIV monoclonal IgG 2G12 was successfully produced in corn with the aim of 
conferring passive protection of vaginal mucosa against HIV infection (Rademacher et al., 
2008). Plant-derived IgG 2G12 was shown to be effective in viral inhibition assays and has 
become a promising cost-effective source for vaginal gel formulations (Ramessar et al., 2008). 
Antibody purification is still a major component of the total cost of goods in plant-made 
recombinant antibody production (Hood et al., 2002). Although biosafety of any 
therapeutic/prophylactic approach involving complex botanical mixes should be exhaustively 
investigated, it is expected that minimally processed extracts from antibody-producing edible 
fruits can be used as safe formulations for mucosal delivery, therefore reducing downstream 
processing costs. Tomato fruits have been studied as successful production platforms for 
recombinant oral vaccines (Walmsley et al., 2003; Zhang et al., 2006b). However, issues such 
as the capacity of fleshy fruits to accumulate functional antibodies, the evolution of antibody 
activity throughout the process of fruit ripening and the formulations that retain neutralizing 
activity have not been addressed before. To address these issues, we have assessed the 
recombinant production in tomato fruit of a phage display-derived human IgA antibody that is 
effective against the model rotavirus strain SA11, and tested the ability of minimally processed 
fruit-derived products to neutralize rotavirus infection in vitro.  
 Besides antibody activity and formulation, an important concern in using edible fruits to 
produce recombinant pharmaceuticals stems from the possibility that the fruit expressing 
pharmaceuticals are mixed with fruit used for food consumption. To address this issue, it has 
been recommended that transgenic fruit should be labelled with distinctive features that help to 
preserve their identity, facilitate traceability and avoid contamination of the food supply. As a 
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proof of this concept, we engineered purple, IgA-producing tomatoes, where Antirrhinum majus 
Rosea1 and Delila transcription factors, known to ectopically activate anthocyanin biosynthesis 
in tomato fruits (Butelli et al., 2008), were incorporated into the transgenic IgA background by 
sexual crossing to obtain tomato-made antibodies in transgenically labelled fruit and fruit 
derived products.  
Results 
Design and selection of human IgA genes for expression in tomato fruits 
Antibody repertoires displayed in phage format provide a flexible and adaptable source 
of neutralizing antibody fragments that can later be transferred to plant expression systems, 
either as antibody fragments or as full-length antibodies (Wieland et al., 2006). An important 
limitation of this approach is the significant heterogeneity of expression levels in the plant, 
apparently due to differences in stability conferred by the antibody variable regions, which 
might be exacerbated by the use of synthetic or semi-synthetic libraries. A possible solution to 
this is the introduction of a quick selection step for in planta stability using transient expression 
analysis, preferably performed in the same plant organ used for the production of the 
compound. Based on this rationale, we designed a set of shuttle vectors to facilitate the transfer 
of the coding sequences for V regions from a phagemid library into plant expression vectors, 
and then took advantage of a fruit transient expression assay (Orzaez et al., 2006) to test the 
expression levels of a subset of the plant produced antibodies against the model rotavirus strain 
SA11. 
DNA fragments which encoded single chain antibody fragments (scFv) that had been 
selected for their recognition of the VP8* peptide of rotavirus VP4 protein were inserted into 
plant expression cassettes carrying the constant regions of human IgA (Supplementary Figure 
1a, b). To gain versatility in the cloning strategy, a Gateway-based set-up was established. Two 
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Gateway pENTR vectors (pENTR_IgH and pENTR_IgL) were generated containing the 
constant regions of IgHα1 and Igλ respectively. Convenient restriction sites were engineered at 
the 5´ ends of each constant region to allow for the direct cloning of VH and VL derived from 
the Griffin.1 phage display library (Supplementary Figure 1a). The variable regions from three 
different anti-VP8* scFv (namely 2A1, 2E4 and 2B3) were introduced into the pENTR vectors 
and transferred to the binary vector pKGW7 through site-specific LR recombination. As a 
result, plant expression constructs were generated containing either the heavy or the light chain 
of a fully reconstituted IgA antibody under the control of the constitutive 35S promoter. 
 The in planta expression of each reconstituted antibody was initially tested using an 
Agrobacterium-mediated transient expression assay. Plant expression vectors carrying the genes 
encoding the heavy and light chains for each antibody to be analyzed were transferred to 
Agrobacterium and infiltrated into tomato fruits. The high co-transformation efficiency 
provided by the fruit agroinjection approach allowed for facile monitoring of the formation of 
full-length IgA in fruit cells. As shown in Figure 1a, only the variable regions derived from 
scFv 2A1 yielded co-expression of heavy chain (HC) and light chain (LC) proteins in planta as 
detected in western analysis under non-reducing conditions. When IgA_2E4 and IgA_2B3 were 
transiently co-transformed, only light chains were detected, whereas their respective heavy 
chains remained undetectable. A 35SCaMV:GFP construct was included in all transformations 
and used to normalize the transformation efficiency in the samples. Transient expression 
analysis using KDEL-tagged versions of the IgA_2A1 heavy and light chains demonstrated that 
ER retention resulted in higher antibody yields (Supplementary Figure 2). The transient 
expression data encouraged us to continue with the stable plant transformation of the IgA_2A1 
idiotype using HC and LC fused to a KDEL peptide as an ER-retention signal. For this purpose, 
an in trans co-transformation strategy was followed (referred as 35S_IgA): tomato explants 
were simultaneously co-inoculated with two Agrobacterium cultures carrying 35S:IgH2A1-kdel 
and 35S:IgL2A1-kdel expression cassettes respectively. 
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 In addition to the above mentioned in trans co-transformation experiment, an in cis co-
transformation approach was also carried out (referred as NH_IgA).  In this case, in order to 
prevent duplication of the 35S promoter, LC was placed under the control of the tomato NH 
promoter. The NH promoter drives high levels of gene expression predominantly in fruits at 
mature-green stage (Estornell et al., 2009). Therefore a dual construct was made (as depicted in 
Supplementary Figure 1b) carrying 35S:IgH2A1-kdel and NH:IgL2A1-kdel expression 
cassettes located within the same T-DNA.  
Transgenic fruits accumulate high levels of mAb 
Primary transformants from cis and trans co-transformation approaches were selected 
by kanamycin resistance and the expression of HC and LC was confirmed by western blots. IgA 
expression levels in T1 generation were evaluated by ELISA and the best performing lines were 
self-pollinated up to T3 for high antibody titers and homozygocity. The description of two 
selected T3 lines per construct (NH_1A-13-2 and NH_III6-2-6 from the NH_IgA approach and 
35S_20A7 and 35S_17A4 from the 35S_IgA approach) is presented here. 
Western analysis of NH_IgA lines showed low IgA levels in leaves when compared 
with fruits (Figure 1b). Interestingly, when samples were analyzed under reducing conditions, it 
was found that not only LC but also HC was nearly absent in leaves, suggesting that HC does 
not accumulate at significant levels in the absence of its cognate LC. Notably, a significant 
portion of the total antibody content in NH_IgA samples under non-reducing conditions was 
present in the form of a 45 kDa band, which reacted both with anti-HC and anti-LC antibodies. 
Furthermore, reducing conditions clearly showed a 25 kDa degradation band that was 
recognized by anti-HC antibody, while the LC remained intact. Together, these observations 
indicate that a significant proportion of total IgA was present in the form of Fab’ fragments, 
probably as a result of the cleavage of the full IgA perhaps in the hinge region. IgA production 
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levels were quantified by ELISA in fruits of the NH_1A-13-2 homozygous line, reaching 15.6 ± 
1.2 µg IgA equivalents /g FW (1.1 ± 0.1% TSP) (Table 1). 
The in trans co-transformation strategy (35S_IgA) resulted in 20% (4 out of 20) of the 
T1 kanamycin-resistant plants showing both HC and LC expression in vegetative tissues. 
Following the same mini-breeding strategy as for the NH_IgA plants, lines 35S_20A7 and 
35S_17A4 were selected for further characterization. In contrast to the NH_IgA lines, 35S_IgA 
plants showed similar expression levels in fruits and vegetative tissues by western blot analysis, 
when gel loads were equalized per total protein content in the sample (Figure 2b). As in the 
NH_IgA approach, a significant part of the total antibody content in leaves and fruits of the 
35S_IgA plants was present in the form of Fab’ fragments, resulting from the association 
between partially degraded HC (Figure 2b, R/HC panel) and intact LC (R/LC panel). In 
absolute terms, 35S_IgA approach resulted in higher levels of recombinant protein production, 
reaching 41.2 ± 2.8 µg of IgA equivalents/g FW in fruits of elite T3 line 35S_20A7, equivalent 
to 3.6 ± 0,8% of TSP (table 1). This remarkable antibody accumulation is partially due to the 
low total protein content in fruits. By comparison, IgA levels of up to 90 µg IgA/g FW were 
achieved in leaves of the same elite plant, representing only 1% of TSP in those organs.  
Accumulation of IgA in fruits is illustrated in Figure 1c, where the full-size LC and the HC 
fragments are clearly observable as 25 kDa bands in Coomassie stained gels, while the full-size 
HC band remains masked by the co-migrating 55 kDa bands in crude fruit extracts.   
Anti-VP8* activity is maintained in late ripening fruits in the form of Fab’ fragments 
 The important physiological changes taking place during fruit ripening are likely to 
affect the accumulation of recombinant antibodies in the fruit. To learn about the effect of 
ripening on antibody accumulation, activity and stability, 35S_20A7 and NH_1A-13-2 tomatoes 
at different ripening stages (mature green, breaker, red and red ripe) were analysed by antigen 
specific-ELISA to assess the specific VP8* binding activity, and by western blot to check for 
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antibody integrity. In addition, red ripened tomatoes which had been air-dried at room 
temperature during one month were also analysed (dried tomato samples). 
 As shown in Figure 2a, the anti-VP8* activity, expressed relative to fruit fresh weight, 
declines stepwise during ripening, with mature green tomatoes showing maximum activity. This 
decline is stronger in NH_1A-13-2 than in 35S_20A7 tomatoes. Remarkably, 35S_20A7 fresh 
red ripened tomatoes, and notably dried tomatoes, still maintain 1/3 of the maximum activity. 
Ripening-associated loss of anti-VP8* activity in 35S_20A7 tomatoes apparently proceeds at 
slower pace than the overall decrease in protein content associated with normal ripening, as 
anti-VP8* specific activity (referred to total protein content) is maintained even in the late 
ripening stages (Figure 2a). When these samples were analysed by western blot (Figure 2b), it 
became clear that a significant fraction of the full-length IgA is converted into Fab’ fragments 
during late ripening. In contrast to full length IgA, Fab’ seems highly resistant to further 
degradation as it is highlighted by the strong Fab’ band observed in 35S_20A7 tomatoes at the 
late ripe stage (Figure 2b, lanes RR and D).    
Minimally-processed tomato-based products show strong anti-VP8
*
 activity 
 The anti-VP8* binding activity of fruit-derived extracts was determined using fruits 
from the elite line 35S_20A7. The assays used antigen-ELISA plates coated with VP8* or with 
BSA as a control. In order to test the resistance of the antibody activity to downstream 
processing, three tomato formulations compatible with long-term conservation and oral delivery 
were assayed, referred to as “juice”, “powder” and “dried juice”.  “Juice” consisted in a clarified 
extract from frozen fruit samples ground in liquid nitrogen with PBS (1:3) (w:v).  The “powder” 
format consisted in freeze-dried ground tomato powder, later reconstituted in PBS using 3 
volumes of the original fresh weight. “Dried juice” consisted in freeze-dried “juice” sample, 
later reconstituted in water using 3 volumes of the original fresh weight. All samples were 
clarified by centrifugation and incubated in serial dilutions in an antigen-ELISA test. Control 
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“juice”, “powder” and “dried juice” samples from wild type Moneymaker fruits also were 
prepared as described above.  For all three products, a strong anti-VP8* binding activity was 
observed, which was not detected in formulations prepared from wild type samples or with 
control assays that used BSA. Antibody binding titers showed consistent behaviour, as all three 
samples reached endpoint titers at 1/512 dilutions (w/v) (Figure 3). The full conservation of 
antibody binding activity in “powder” and “dried juice” formats is particularly promising for 
oral delivery, as dried formulations also ensure an increase in antibody dosage. In the case of 
35S_20A7 tomatoes, because dry weight represents 6% of the total fresh weight, the 
recombinant antibody levels in the “powder” samples reach remarkable levels up to 0.68 mg of 
IgA equivalents per gram of dry weight (Table1).    
Minimally processed fruit samples show strong rotavirus neutralization activity  
 Once the VP8* binding activity of the IgA_2A  produced in the fruit was determined, 
the next steps consisted of (i) testing the rotavirus neutralizing activity of the recombinant 
antibody expressed in fruit, and (ii) evaluating the possible effect of the context conferred by the 
remaining components of the tomato extract in the neutralization capacity. Affinity purified 
recombinant IgA was obtained from 35S_20A7 mature green fruits using SSL7-agarose 
chromatography columns. The SSL7 protein specifically binds the hydrophobic interface 
between the Cα2 and Cα3 domains of the Fc portion of the HC. The purification steps were 
monitored by antigen-ELISA and western blot, and the presence of contaminant proteins in the 
final elution was tested with silver-stained gels. Single-step affinity purification with SSL7-
agarose resulted in moderate 3.5 x enrichment in antibody activity with respect to the crude 
starting extracts (Figure 4a). A significant part of the total activity was detected in the flow-
through fraction. This is probably because the Fab’ fragments do not bind SSL7 due to the lack 
of Fc domain, as observed in the western blot analysis in Figure 4b. Silver-stained PAGE of 
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eluted fractions in Figure 4b illustrate the level of purification of the full-size recombinant IgA 
obtained after a single-step affinity purification with the SSL7 agarose. 
 Neutralization activity against SA11 rotavirus was determined by means of 
immunofluorescence assays on MA104 cell monolayers. The assays were performed by a 
previous incubation of rotavirus with serial dilutions of the IgA samples, followed by the 
infection of the formed monolayer with the resulting mixture. In a first assay, serial dilutions of 
the SSL7-purified IgA were compared with samples treated with PBS as mock treatment 
controls. The neutralization capacity of the sample is represented in Figure 5a as the percentage 
of foci reduction with respect to the number of foci produced by the control treatment.  IgA 
dilution series started with 30 g/mL, with minimum significant titers (>60%) obtained with 
3.75 µg/mL of IgA, and a calculated IC50 value of 2.5 g/mL.  
 Once the neutralization capacity of the recombinant IgA produced in tomato fruit was 
demonstrated, different assays were done using different minimally-processed tomato fruit 
extracts, all of which were suitable candidates for therapeutic delivery. For this purpose, the IgA 
content of “juice” and “powder” samples from the 35S_20A7 tomatoes was estimated by 
ELISA. Serial dilutions of the same samples were assayed for rotavirus neutralization along 
with equivalent “juice” and “powder” samples from wild type tomatoes as reference controls. 
Both “juice” and “powder” samples of IgA fruits showed similar neutralization curves, with 
IC50 values of 1.8 and 2.0 g/mL respectively (Figure 5b). In these samples, neutralization titers 
>60% were obtained with 3.7 µg/mL of IgA equivalents. This approximately corresponds to a 
1/12 dilution of the original IgA content in fresh fruits and 1/192 (w:w) of the IgA abundance in 
the fruit powder.  Although IC50 values of purified and un-purified IgA samples are very similar, 
it is interesting to notice that “powder” and to a lesser extent “juice” samples, when employed at 
low dilutions (equivalent to 7.5 and 15 g IgA/mL) are more effective in foci reduction than 
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equivalent concentrations of purified IgA (Figure 5a). An image of the effect of tomato IgA on 
the reduction of rotavirus infective foci is shown in Figure 5c. 
Rosea1 and  Delila transgenes can be used to confer identity preservation to IgA-
expressing tomatoes 
 Recombinant biofactory strategies involving food crops may benefit from the 
introduction of labelling traits. Recently, transgenic Del/Ros1 MicroTom tomato fruits with an 
intense purple colour have been described (Butelli et al., 2008). Several traditionally red tomato 
cultivars are known to display a bronze coloration due to accumulation of anthocyanins in the 
peel. In contrast, Del/Ros1 accumulates large amounts of anthocyanins not only in the peel of 
the fruit, but also in the pericarp and jelly tissues. This feature makes Del/Ros1 tomatoes ideal 
for transgenic labelling and makes traceability easier for both fruit biofactories and their derived 
“juice” and “powder” products.  
 Del/Ros1 genotype was initially introduced into the dwarf, cherry tomato MicroTom 
cultivar. However, large globe-type tomatoes are preferable in fruit biofactory strategies to 
maximize yields of fruit material.  With this goal in mind, purple-fruited MicroTom Del/Ros1 
plants (kindly provided by Prof. Martin) were crossed with globe-type wild type Moneymaker 
plants. The offspring showing combined globe-type and purple phenotypes were single-seed 
selected up to the F7 generation. A plant from the F7 generation was sexually crossed with a T1 
35S_IgA expressing line (35S_3), and the offspring of this cross were screened in an antigen-
ELISA for IgA expression. Eight out of thirteen plants were found to be IgA positive and were 
grown to maturity (referred as CR lines). All of them resulted in a purple-coloured fruit 
phenotype. Moreover, this colour trait was maintained during fruit processing steps, as “juice” 
and “powder” samples showed a clearly distinguishable purple colour, in contrast with the light 
red colour of wild type derived products (Figure 6a). Fruits from the F1 generation CR lines 
were then tested for IgA expression, showing maximum antibody levels of 6.2 µg/g FW (0.8% 
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TSP). CR lines were then self-pollinated to F3 generation. As a result, an elite F3 plant with 
purple fruit, called CR2-3-8, showed maximum IgA expression levels of 33.5 ± 4.2 µg IgA/g 
FW, equivalent to 1.9  ± 0.3% TSP, which is a level comparable to that found in the red fruited 
T3 35S_20A7 line (shown in Table 1). Endpoint ELISA titers of tomato powder were also 
conducted, showing titering curves consistent with the estimated IgA levels and confirming the 
conservation of the biological activity of the IgA expressed in the purple fruit (Figure 6B). 
Finally, the neutralization activity of IgA powder from purple fruit was confirmed in VN assays 
(Figure 6C). In these assays, disruption of the cell monolayer was observed when samples 
derived from purple powder were incubated at low dilutions (up to 1:12 w:v, not shown). To 
dissect any possible effect of the anthocyanin background on the cell monolayer, VN titers of 
the CR2-3-8 “powder” samples were performed at dilutions above the cell disruption threshold 
(1:24 w:v onwards) using an IgA-free sibling purple fruited line CR2-3-5 as a control. Purple 
IgA expressing tomato fruit samples also strongly neutralized rotavirus, with a calculated IC50 
value of 1.98 µg/mL of IgA (Fig 6c), a value similar to that observed previously in the red 
tomato “powder”. 
Discussion 
Diarrheas caused by enteric pathogens kill an estimated 2.5 million infants worldwide 
per year (Kosek et al., 2003), and 500.000 of the fatalities are caused by rotavirus alone 
(Parashar et al., 2003). Recently, two jennerian vaccines against rotavirus have been 
successfully launched. However challenges remain regarding the potential effectiveness of oral 
live vaccines in developing countries in view of the prevalence of competing intestinal flora in 
children, the occurrence of mixed infections, the high levels of maternally transmitted 
antibodies and general malnutrition. Recombinant production of rotavirus antigens in plants has 
been proposed as an alternative to traditional production platforms (Birch-Machin et al., 2004; 
Choi et al., 2005).  In addition, passive oral immunization emerges as a complementary strategy, 
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as this approach has repeatedly been shown effective against enteric infections (Corthesy, 
2002). In this context, the availability of an inexpensive source of neutralizing antibodies for 
mucosal protection might serve as a valuable complement to current vaccination strategies. This 
work shows that recombinant antibodies against the model rotavirus strain SA11 accumulate to 
considerable levels in tomato fruits and that neutralizing antibody preparations can be obtained 
from edible fruit tissues using extremely simple processing steps. Therefore, these results 
suggest that the production of antibodies in edible fruits can serve as an economically viable 
complement for combating enteric diseases, particularly in developing countries. 
 Oral delivery of minimally-processed products derived from edible plant organs has 
been successfully assayed both in active and passive immunization models. In active 
vaccination strategies, the context provided by the plant tissue has been eventually shown to 
positively influence protection. This might be related to the natural antigen encapsulation 
provided by plant cells and the adjuvant effect provided by some of the components of the plant 
extract. The alkaloid tomatine has been proposed as an adjuvant, potentiating the response 
observed when tomato-made norovirus VLPs were used for oral delivery (Zhang et al., 2006a). 
In another example, oral boosts with chloroplast-made plague fusion antigen F1-V without 
standard adjuvants but delivered as crude plant material, performed as well as adjuvated sub-
cutanous boosts (Arlen et al., 2008). More recently, a chloroplast-based strategy using lettuce as 
production platform conferred dual protection against cholera and malaria in mice (Davoodi-
Semiromi et al., 2010). In the veterinary field, oral passive protection using plant extracts has 
been sucessfully reported in pigs for protection against transmisible gastroenteritis virus 
(Monger et al., 2006) and in poultry for protection against coccidiosis (Zimmermann et al., 
2009). In the latter case, pea-derived scFv against Eimera protozoa showed an enhanced 
prophylactic activity. It is likely that protease inhibitors present in pea seeds might contribute to 
the higher stability of the protein and, therefore, enhanced protection. Herein we show that 
preparations of IgA-expressing tomato fruit are at least as efficient as purified recombinant IgA 
 15 
in neutralizing rotavirus infection, indicating that (i) neutralizing activity is not affected by 
processing and (ii) the Fab’ fragments predominant in fruit tissues are efficient for virus 
neutralization. Moreover, the ”juice” and especially the “powder” formulations seemed even 
more effective than purified IgA in preventing rotavirus infection. This could be explained by a 
protective role of the extract in the stability of the antibody, or by the contributors of additional 
components of the extract acting cooperatively with the antibody in neutralizing the infection. 
The effect of the edible plant extracts to enhance virus neutralization needs further investigation, 
as it may boost the effectiveness of passive protection strategies.  
 Tomato is a highly productive largely self-pollinated crop that is well adapted to green-
house cultivation under the confined conditions required for molecular farming. Having low 
protein content per fresh weigh, fruits have sometimes been discarded as potential biofactories. 
However, as demonstrated here, once water is removed from the fruit by drying, the antibody 
production in fruit approaches highly competitive levels of gram per Kilogram of dry weight. 
Considering an average production of 6 Kg of tomato (FW) per plant, current IgA yields in 
fruits would lead to production levels reaching 0.5 grams of antibody (IgA + Fab’s) per tomato 
plant, which can be administered as semi-crude formulations where the remaining components 
are Generally-Regarded-As-Safe. Moreover, downstream processing may benefit from “state of 
the art” tomato food/beverage processing technology. For instance liquid spry-drying, a process 
increasingly used in antibody formulation (Maa et al., 1998), is also employed in the food 
industry for the production of tomato powder (Santos de Sousa et al., 2008). Furthermore, the 
availability of single-step affinity purification systems as the SSL7-agarose described here 
offers an economically relevant tool to obtain partially-purified formulations with increased 
concentration and/or safety profile.  
 Zhou and co-workers (Zhou et al., 2008) reported an almost complete disappearance of 
HIV recombinant antigens upon ripening in transplastomic tomato fruits, and therefore 
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proposed the use of green-fruited tomato varieties for molecular farming. Ripening seems to 
affect the protein biosynthesis capacity in plastids more drastically than in the 
nucleus/cytoplasm. We found only a moderate decrease in activity levels of nuclear encoded 
antibody in ripened fruit. Moreover, the stability of Fab’ fragments during ripening and post-
harvest seems key in the maintenance of the neutralizing activity. The use of green-fruited 
tomatoes is nevertheless an interesting proposal also for nuclear-encoded transgenes, as it may 
contribute to further increases in yields. Further pyramiding of ripening-related genes could lead 
to new tomato varieties better adapted to molecular farming. For example, by disrupting 
ripening-associated disadvantageous traits (e.g. protease activity or chromoplast transition), 
while preserving others (e.g. reduction of anti-nutrients or responsiveness of engineered 
promoters), the deleterious effects of ripening on pharmacological production may be obviated. 
IgA_2A1 made in tomato fruit was engineered for in planta production by inserting the variable 
regions of scFv_2A1 into the constant regions of human IgA, and placing the resulting antibody 
coding regions under the control of plant promoters. A single-chain 2A1 antibody fragment was 
previously isolated in a phage display screening against VP8* peptide, a rotavirus surface 
antigen known to induce neutralizing antibody responses (Higo-Moriguchi et al., 2004). It is 
generally accepted that broad-spectrum passive immunization against intestinal pathogens 
including rotavirus will benefit from polyclonal mixes of neutralizing antibodies. This could be 
achieved either by combining different monoclonal transgenic lines or by engineering single 
transgenic lines producing a combination of monoclonal antibodies. In both cases, phage 
display constitutes an interesting source of antigen-binding variable regions for in planta 
production. However, we and others (Ballester et al., 2010; Verma et al., 2010; Wieland et al., 
2006) have repeatedly observed strong differences in the stability of different phage-display 
derived scFv, or scFv-reconstituted full-size antibodies when expressed in planta. Therefore, 
when using phage display as a source for variable antibody regions, it is important to identify 
stable antibody idiotypes before undertaking stable transformation. For this it is crucial to 
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establish (i) flexible tools for scFv grafting and (ii) fast in planta expression systems, preferably 
in the same tissues in which the final production is intended. In our lab we previously developed 
a transient expression system for tomato fruits known as fruit agroinjection, which allows facile 
construct-testing in fruit tissues such as placenta, gel and inner pericarp (Orzaez et al., 2006). In 
addition, we have adopted a grafting procedure based on restriction/ligation and Gateway 
recombination that facilitates the cloning of new variable regions into IgA constant regions. The 
need for an in planta selection step is illustrated in this work. We took advantage of the 
aforementioned tools to select among three anti-VP8* full-length antibodies, two of which had 
to be discarded prior to stable transformation as they showed very low levels of heavy chain 
accumulation. 
 In the final design of the recombinant antibody, a number of additional decisions were 
made. The endogenous signal peptide was substituted with the signal peptide of a pectate lyase 
expressed in fruit to ensure processing of the IgA protein in the fruit tissues. IgA was chosen as 
full antibody isotype, as it will facilitate, if required for increased efficiency, further conversion 
into secretory IgA (Crottet and Corthesy, 2001; Ma et al., 1995). Two transformation 
approaches were undertaken, involving in trans and in cis co-transformation, the latter using an 
additional fruit-operating NH promoter (Estornell et al., 2009). The NH_IgA approach resulted 
as expected, in very low expression in vegetative tissues compared with fruits. Fruit-specific 
expression may be appreciated as a biosafety measure, and may avoid the diversion of synthetic 
capacity of the crop towards unprofitable protein production in vegetative tissues. However, in 
this case, the in trans strategy employing the same 35S promoter for both HC and LC yielded 
higher IgA levels in fruits. The 35S promoter has been previously shown to operate at high 
levels in fruits during development and ripening (Estornell et al., 2009) and may have 
contributed to the high IgA expression levels in spite of a general decline in transcriptional 
activity that takes place during late ripening.  
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 The high accumulation of ER-retained IgA_2A1 observed in transient fruit expression 
assays prompted us to use ER-retention in stable versions of IgA expression. This effect has 
been reported repeatedly for plant-made antibodies (Orzaez et al., 2009) and may be indicative 
of a lower level of protease activity in the ER milieu. ER-retention prevents complex 
glycosylation in the Golgi apparatus, particularly the addition of fucose and xylose plant-
specific residues. It has been argued that the presence of immunogenic fucose and xylose in 
plant-made antibodies could lead to allergic reaction, and ER retention could be used as a 
preventive measure (Sriraman et al., 2004). However, it is unlikely that these residues are 
allergenic through the mucosal route given the continuous exposure of mucosa to plant 
glycosylation patterns in food. Also, in the design of hIgA_2A1 we incorporated the HCα1 
coding region. IgA1 has an extended shape compared with IgA2, as a result of an elongated 
hinge region. It has been proposed that the IgA1 shape facilitates the cross linking of viral 
particles, and, therefore might provide specialized functions in the protection against viral 
pathogens (Bonner et al., 2009). 
 Edible plant organs provide clear advantages in particular molecular farming 
approaches. However the concerns about contamination of the food chain with engineered 
contents is often reasonably raised when pharmaceuticals are produced in food crops. We 
propose here the use of natural coloured plant compounds for labelling transgenic crops by 
means of metabolic engineering. A relatively small amount of otherwise health-promoting 
compounds such as anthocyanins, a natural component in many edible berries, is sufficient to 
label IgA-producing plants. These compounds confer an intense purple colour ensuring the 
traceability of transgenic fruits and their derivatives. F1 plants coming from the initial crossing 
of purple and IgA expressing plants showed considerably lower IgA levels than those measured 
in the elite T3 35S_IgA expressing lines. This raised the question of a possible dilution effect of 
the recombinant protein production in the anthocyanin background. However, when purple IgA 
plants were bred up to F3, a considerable increase of IgA content was observed, reaching levels 
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of 33.5 g IgA/g FW, close to those reported for red IgA plants (41.2 g/gFW). This indicates 
that the anthocyanin background has a minimal effect on the levels of IgA accumulation in 
fruits. Moreover, IgA from the transgenically labelled purple tomatoes also showed anti-VP8* 
binding and rotavirus neutralizing activities similar to those described for red tomatoes, again 
indicating that IgA activity is not affected by the presence of anthocyanins. Disruption of cell 
monolayers was observed in VN assays when samples derived from purple “powder” were 
incubated at low dilutions. It has previously been reported that some phenolic compounds may 
react with constituents of certain cell culture media (Long et al., 2010). These reactions can 
result in the oxidation of phenol to produce a range of toxic products such as H2O2. These 
effects can be regarded as artifactual as they result from the interaction with the culture media, 
and are not likely to take place in vivo.  Moreover, when VN assays were performed at dilutions 
above the cell disruption threshold, the neutralizing effect of recombinant IgA was evident.  
 A further degree of safety can be achieved by genetically linking the antibody and the 
Del/Ros1 modules (e.g. including both modules in the same T-DNA). The same synthetic 
biology rational can be used to include additional safety modules as male sterility as well as any 
other with relevance to antibody production as glycoengineering, decreased protease activity, 
etc. leading to the design of highly optimized platforms for molecular farming (Sarrion-
Perdigones et al., 2011). 
 This is, to our knowledge, the first report showing viral neutralization activity of a plant 
produced antibody in minimally processed edible fruit extracts. The results support the need for 
a detailed investigation of the biosafety and in vivo effectiveness of fruit-based passive 
immunization. Moreover, we created the first example of a biofortified plant crop additionally 
displaying prophylactic activity. The model plant designed here is an example of how gene 
stacking, either by sexual crossing or by other means, can lead to new agricultural products with 
added-value and new applications. The introduction of four transgenes (HC, LC, Ros1, and Del) 
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in a single tomato plant resulted in a completely new product: a transgenically labelled, orally 
safe, inexpensive fruit juice with a health-promoting (antioxidant) activity (Butelli et al., 2008) 
and anti-rotavirus prophylactic potential.  
Experimental procedures 
DNA constructs and vectors 
 The DNA sequences corresponding to the constant regions of human alpha heavy 
(HCα) and lambda light (LCλ) antibody chains were obtained from the human library clones 
EHS1001-9024643 and EHS1001-9024145 respectively (Open Biosystems, Huntsville, USA). 
LCλ was PCR amplified in a nested reaction using D06mar01 and D06mar07 oligos as 
overlapping forward primers and D06mar08 as reverse primer. D06mar01 and D06mar07 
overlapping primers were used to fuse to the 5´end of LCλ a number of elements, namely an 
attB1 recombination site, a Kozak sequence, the signal peptide (SP) from the tomato pectate 
lyase and a small polylinker containing ApaLI, and NotI restriction sites. In another construct, 
the D06mar08 primer incorporated a KDEL peptide, a stop codon and an attB2 recombination 
site in the 3´ end of the LCλ coding region (Supplementary Table 1). The resulting LCλ 
expression cassette, still lacking the sequence corresponding to the variable region of the light 
chain (VL) was BP-cloned in pDNOR221 vector, generating an ENTRY vector named as 
pENTR_LCλ. In a similar fashion, a pENTR_HCα vector was created for the convenient 
cloning of variable regions of the heavy chain into an IgCα frame. In this case, cloning of HCα 
was preceded by a step of directed mutagenesis designed to silently remove NcoI and XhoI sites 
from HCα coding sequence. For this purpose, HCα was pre-amplified in three contiguous 
fragments using oligonucleotide pairs D03Mar00/ D03Mar19, D06Mar03/D03Mar04 and 
D03mar20/D03Mar06 respectively, and subsequently joined by overlapping PCR. The resulting 
mutagenized HCα was re-amplified in a nested reaction with D06mar01 and D06mar02 as 
forward primers, which incorporated attB1, the pectate lyase SP and NcoI/XhoI cloning sites. 
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At the 3’ end, the D06Mar06 primer incorporated a stop codon, the KDEL peptide and attB2. 
The resulting HCα expression cassette was BP cloned into pDONR221 vector yielding 
pENTR_HCα vector. 
 The sequences of the variable antibody regions reacting against VP8* were cloned from 
a previously described anti-VP8 scFv collection selected from the phage display human 
antibody library Griffin.1 (Monedero et al., 2004). The Griffin.1 library is a large naïve human 
scFv phagemid library (total diversity of 1.2 × 10
9
) constructed from synthetic V-gene segments 
made by recloning the heavy-chain and light-chain variable regions from the lox library vectors 
(Griffiths et al., 1994) into the phagemid vector pHEN2. VL fragments (2A1, 2B3 and 2E4) 
were ApaLI/NotI digested and cloned into pENTRY_LCλ ApaLI/NotI sites, generating 
pENTR_IgL vectors. In parallel, VH fragments (2A1, 2B3 and 2E4) were NcoI/XhoI excised 
from Griffin.1 vector and cloned in the equivalent sites of pENTR_HCα, generating 
pENTR_IgHα vectors. To harbour the expression cassettes of the individual antibody chains, 
pBINJITGW and pKGW7.0 were used as destination vectors. pKGW7.0, containing 35S 
promoter and terminator was kindly provided by Dr Karimi (Karimi et al., 2002). pBINJGW 
was engineered by introducing a Gateway cassette (Invitrogen, Carlsbad, USA) in the SmaI 
site of pBINJIT plasmid, following manufacturers procedures. Binary expression vectors for 
heavy and light antibody chains were obtained by performing LR reactions between ENTRY 
vectors (e.g. pENTR_IgL_2A1, pENTR_IgHα_2A1) and binary destination vectors, generating 
plant antibody expression clones (e.g. pEXP_ 35SIgL_2A1 and pEXP_ 35SIgHα_2A1).  
 Heavy and light chains expression cassettes were also combined in a single binary 
vector under the constitutive 35S and the fruit-operating NH promoters respectively. For this 
purpose, the IgL_2A1 coding region was PCR-amplified using primers L07Nov07 and 
L07Nov08 containing attB4R and attB3R extensions and BP-recombined into pDONR221P4r-
P3r (Invitrogen), generating pENTR4R3R_IgL2A1. A triple gateway recombination reaction 
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was then performed between vectors pENTR1-4_NH, pENTR3-2_Tnos, both belonging to the 
previously described pENFRUIT collection of combinatorial vectors (Estornell et al., 2009), 
and pENTR4r3r_IgL2A1, using pKGW.0 as a destination vector. In this way, an expression 
cassette was generated comprising the NH promoter fused to IgL-2A1 and the Tnos terminator. 
The whole 4.9 Kb expression cassette was PCR-amplified using primers L07Jun05 and 
L08Jan01, containing AscI and SalI recognition sites respectively. The resulting PCR fragment 
was digested with AscI/SalI and cloned into pEXP_35SIgHα_2A1, generating the binary 
plasmid pEXP_35SIgH_NHIgL, which combines heavy and light antibody chains under the 
control of two different promoters both operating in the tomato fruit. 
Tomato transformation, plant material and sample preparation 
Plasmids were transferred to Agrobacterium tumefaciens LBA4404 strain by 
electroporation and used for tomato stable transformation (var. Moneymaker), as described 
previously (Ellul et al., 2003). For transient expression, plant expression plasmids were 
transferred to Agrobacterium tumefaciens strain C58 and assayed transiently in MicroTom 
fruits, as described previously (Orzaez et al., 2006). For sample preparation, plant tissues 
(leaves and tomato fruit) were ground with a mortar and pestle to a fine powder under liquid 
nitrogen and stored at -80º until used. For “Juice” samples, proteins were extracted with three 
volumes (w/v) of phosphate-buffered saline (PBS) pH 7,4. After mixing, the suspension was 
centrifuged twice at 4º C at maximum speed and the supernatant was immediately used for 
further analysis. For “Dried Juice” samples, total protein was extracted in the same manner, 
followed by a 24 h freeze-drying step. The sample was reconstituted in three volumes of water 
(w/v) for analysis. The “Powder” samples were obtained from fine tissue powder after a 24 h 
freeze-drying treatment; total protein was extracted with three volumes of PBS pH 7,4 (w/v), 
centrifuged twice at 4º C at maximum speed and the supernatant was used for the analysis. 
VP8* Rotavirus surface protein production 
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Recombinant VP8* was obtained from pQEVP8* transformed Escherichia coli M11. 
Plasmid pQEVP8* was kindly provided by Dr. Monedero from Instituto de Agroquímica y 
Tecnología de Alimentos (IATA, Valencia). VP8* expression was performed using the 
QIAexpressionist protocol (www.qiagen.com). Frozen cell pellets were thawed in 20 mM Tris-
HCl pH 8.0. Cells were lysed by sonication on ice (6 x 25 sec) and washed with buffer A (20 
mM Tris-HCl, 0.5 M NaCl, 2 M Urea and 2% Triton X-100) to isolate inclusion bodies. After 
15 min 18.000 rpm spin, cells were sonicated (6 x25 sec) one more time and washed again with 
the same buffer. A last wash with urea-free buffer A was made.  
Inclusion bodies were solubilised with 20 mM Tris-HCl, 0.5 M NaCl, 6M Guanidine 
HCl, 5 mM Imidazole and 1 mM 2-β-mercaptoethanol at pH 8.0. The sample was stirred at 
room temperature for 1 hour and then centrifuged for 15 min at high speed. The remaining 
particles were removed by passing the sample through a 0.22 µm filter. Purification was 
performed using HisTrap HP affinity columns (GE Healthcare, Buckinghamshire, UK) 
following manufacturers procedures. Protein refolding in column was performed with 30 mL of 
a lineal 6-0 M urea gradient at a flow rate of 1mL/min, starting with buffer B (20 mM Tris-HCl, 
0.5 M NaCl, 6 M urea, 1 mM 2-mercaptoethanol) and finishing with urea-free buffer B. The 
refolded protein was eluted using a 10 mL lineal gradient starting with buffer C (20 mM Tris-
HCl, 0.5 M NaCl, 20 mM  Imidazole, and 1 mM 2-mercaptoethanol) pH 8.0 and ending with 
the same buffer C supplemented with 500 mM imidazole. 
ELISAs for detection of VP8* binding activity and recombinant immunoglobulin A 
determination 
Plates (Corning, New York, USA) were coated overnight with 10 µg/ mL of 
recombinant VP8* for detection of VP8* binding activity or 2 µg/ mL of anti-human IgA α 
specific (Sigma Aldrich St. Louis, USA) for IgA determination, in coating buffer (50 mM 
carbonate buffer pH 9,8) at 4º C. Plates were then washed 4 times in PBS and blocked with a 
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2% (w/v) solution of ECL Advance
TM
 Blocking agent (GE Healthcare) in PBS-T (0.1% (v/v) 
Tween 20 in PBS). Samples were diluted in PBS as required for each assay and incubated for 1 
hour at room temperature. After incubation, plates were washed 4 times in PBS and the anti-
human IgA α specific-HRP 1:5000 (Sigma Aldrich) in 5% blocking buffer (GE Healthcare) in 
PBS-T was added and incubated for 1 h at room temperature. After 4 PBS washes, the substrate 
(o-phenilenediamine from Sigma Aldrich) was added and the reactions were stopped with 3M 
HCl. Absorbance was determined at 492 nm. As a control for specificity, plates were coated 
with 10 g/ mL of bovine serum albumin (BSA). A sample was considered positive when its 
absorbance was at least 3 times higher than the absorbance value of the same sample in the 
control. Specific VP8* binding activity was estimated using serial sample dilutions, dividing the 
absorbance at 492 nm of those dilutions falling within the lineal range, by the total protein 
content of each sample (mg). A standard curve from 0.8 µg/mL to 0.1 µg/mL of commercial 
IgA from human colostrum (Sigma Aldrich) was made to calculate the concentration of IgA in 
the different samples. IgA concentration in each sample was obtained by interpolation with the 
IgA standard curve. For IgA quantification in elite lines, three samples from each elite line were 
analyzed and the mean ±SD for each line was calculated. 
SDS-PAGE and western blot analysis 
Proteins were separated by SDS/PAGE in 10% and 3-8% denaturing gels (Invitrogen). 
Gel staining was carried out either with Coomassie blue or silver staining following standard 
procedures. For western blot analysis, blots were incubated with 1:20.000 anti-human IgA α 
specific-HRP (Sigma Aldrich) for the detection of the heavy chain (HC) and 1:10.000 Anti 
human λ light chain (Sigma Aldrich) followed by 1:10.000 µg/mL HRP conjugated anti-rabbit 
IgG (GE Healthcare) for the detection of the light chain (LC). Blots were developed with ECL 
Plus western blotting Detection System (GE Healthcare). 
Protein SSL7 affinity purification 
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Protein extracts prepared as explained previously were further clarified using a 0.22 µm 
Stericup (Millipore, Massachusetts, USA) on ice. The clarified extract was directly used for 
purification with staphylococcal superantigen-like protein 7 (SSL7) agarose columns from 
InvivoGen following manufacturer´s protocol with minor modifications. Wash Buffer was 
substituted by PBS (0.1 M phosphate, 0.1 M NaCl pH 7.4). Dialysis was not needed as the 
samples were already in PBS and Elution neutralization was carried out mixing with PBS 1:1 
(v/v). 
Neutralization assays 
Tomato-IgA neutralization of rotavirus SA11 strain was assessed by immunofluorescent 
focus reduction assays on MA104 (Health Protection Agency Culture Collection) cell 
monolayers in 96 well cell culture microplates (Corning) infected with rotavirus (Asensi et al., 
2006). The plates were coated with 2 x 10
4
 cells per well in MEM (minimum essential medium 
from Gibco-Invitrogen) supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, 2 
mM glutamine, 0.7%  CO3H and 10% fetal bovine serum (FBS) and incubated for 24 h at 37ºC 
in a CO2 stove until the monolayers were confluent. Rotavirus suspensions (at two different 
concentrations, 2 x 10
3
 and 1 x 10
4
 fluorescing cell-forming units per mL [f.f.u./mL]) in MEM 
without FBS were activated with 10 µg/mL of trypsin type IX (Sigma Aldrich) prior to the 
incubation with serial dilutions (1:2 to 1:256) of IgA samples in MEM (FBS-free), and the 
resulting mixes were used to infect the monolayers (1 h incubation at 37ºC). After incubation, 
the monolayers were washed with MEM and incubated for 18 h in MEM containing 1 µg/mL 
trypsin at 37ºC in a CO2 stove. Four different IgA samples were used in the different assays: ssl-
7 purified recombinant IgA in PBS, 35S_20A7 clarified fruit extract (“juice”), freeze-dried 
tissue samples from 35S_20A7 and CR2-3-8 fruits reconstituted in PBS (“powder”). PBS, 
“juice”, and reconstituted “powder” from fruits of wild type Money Maker or IgA-free purple-
fruited CR2-3-5 plants were used as mock solutions for comparisons.  All fruit samples were 
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collected and processed between 2 and 4 days after reaching the breaker stage. After incubation, 
monolayers were fixed with 100 µL/well of 1:1 (v:v) methanol-acetone for 15 min and then 
washed with PBS. An anti-rotavirus VP6 monoclonal antibody in PBS 1% BSA (1:80) was 
applied as the primary antibody for 1 h at 37ºC, followed by three washes with PBS. The 
secondary antibody was an anti-mouse IgG FITC-labeled (SIGMA) (1:400). The monolayers 
were washed 3 more times with PBS and stained with Evans blue for 5 min, washed again with 
PBS and 20 µL of mounting fluid (Millipore) were applied to each well. Images were obtained 
by excitation with 480 nm light and acquired at 6,3x magnification factor with a Leica MZ16F 
binocular equipped with a Leica DFC300FX digital camera and Leica application suite 
software. The 50% inhibiting concentrations (IC50) were calculated by the method of Reed and 
Muench (Reed and Muench, 1938), using the concentrations present during the antibody-virus 
preincubation step. 
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Tables 
 
Table 1. Total soluble protein (TSP) and IgA levels referred to TSP, fresh weigh (FW) and dry 
weight (DW) of diferent tomato elite lines. 
  
Figure legends 
Figure 1. Western blot analysis of IgA expression in tomato. (a) Transient expression 
analysis of scFV-derived 2E4, 2B3 and 2A1 antibodies using direct fruit-agroinjection. Fruits 
were co-agroinjeted with ER-retained heavy and light antibody chains, together with GFP as 
internal control. (b) Western blot analysis of leaves and fruits from best-permorfing T3 lines 
from in cis (NH) and in trans (35S) transgenic approaches. Three fruits from each elite T3 plant 
were pooled in each representative sample. All fruits were labelled at breaker stage and 
collected bewteen 48 and 72 hours later (c) Comparison between fruit extracts from of 
35S_20A7 and wild type (WT) plants. Samples were resolved under either reducing (R) or non-
reducing (NR) conditions and decorated using anti-heavy chain antibody (HC), anti-light chain 
antibody (LC), anti-GFP antibody (GFP) or by Coomasie staining (CS). HS lane contains 
control human serum.  
Figure 2. IgA accumulation profile during tomato fruit ripening. (a) Evolution of anti-VP8* 
activity in fruit extracts of 35S_20A7 and NH_1A-13-2 elite plants referred to fresh weight 
(light grey) and total protein content (dark grey columns). (b) Western blot analysis of the same 
ELITE LINES (T3) GENOTYPE TPS (mg/gFW) IgA (% TSP) IgA (µg/gFW) IgA (µg/gDW) 
35S_20A7 IgH/IgL 1,2 ± 0,2 3,6 ± 0,8 41,2 ± 2,8 686,9 ± 46,7 
NH_1A-13-2 IgH/IgL 1,4 ± 0,1 1,1 ± 0,1 15,6± 1,2 259,6 ± 19,7 
CR2-3-8 IgH/IgL/Ros1/Del 1,7 ± 0,1 1,9 ± 0,3 33,5± 4,2 558,3 ± 70,3 
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fruit samples as in (a). Samples were resolved under either reducing (R) or non-reducing (NR) 
conditions and decorated using anti-heavy chain (HC) or anti-light chain antibodies (LC). The 
selected fruit developmental stages were: Mature green fruits (MG), corresponding to fully 
expanded green fruits (4-5 weeks after anthesis); Breaker fruits (BK) turning yellow/red, Red 
fruits (R), harvested between 5 and 12 days after breaker stage; red ripe fruit (RR), harvested  
between 14 and 21 days after breaker stage; and dry (D) tomatoes, harvested at the red ripe 
stage and stored at room temperature for one month. HS is a sample of human serum. All 
samples were obtained by pooling three fruits from each developmental stage and analyzed in 
triplicate with bars representing standard error. 
Figure 3. End-point antigen-ELISA titering of minimally-processed fruit-derived 
products. (a) “Juice” is a clarified fruit extract. (b) “Powder” is freeze-dried tissue reconstituted 
in PBS. (c), “Dried Juice” is a freeze-dried “juice”reconstituted in PBS. Binding activity refers 
to the absorbance at 492 nm after 15 min incubation. Samples consisted in 2-3 pooled fruits 
from each elite or control plant, harvested 2-4 days after the breaker stage. All samples were 
titered in triplicate against VP8* or BSA, with bars representing standard error. 
Figure 4. SSL7-based affinity purification of IgA from tomato fruits. (a) Specific Anti-
VP8* activity measured in the different fractions of the purification process. (b) SDS-PAGE 
and western analysis of the starting tomato crude extract (CE) and the final SSL7-agarose eluted 
fraction (EL). SDS-PAGE gels were silver-stained (SS) to asses purity, and western blot 
analysed to detect heavy chain (HC) and light chain (LC) under both reducing (R) and non-
reducing (NR) conditions.  
Figure 5. In vitro rotavirus neutralization assays. Trypsin-activated rotavirus of SA11 strain 
(10.000 ffu/mL) were pre-incubated for 1h with serial dilutions of IgA-containing samples or 
equivalent control samples and used to infect MA104 cell monolayers (2 x 10
4
 cells/well). 
Infective foci were detected after 18h by immunofluorescence and analyzed in triplicate with 
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bars representing standard error. (a) Neutralization titers of affinity purified tomato-made 
IgA_2A1. (b) Neutralization titers of minimally processed products. IgA content in “Juice” and 
reconstituted “Powder” samples was estimated by sandwich ELISA and equalized with the 
addition of PBS. Equivalent wild type “juice” and “powder” samples were equally diluted in 
PBS and used as controls to estimate the percentage of neutralization of each sample. All 
samples consisted of at least three pooled fruits from either elite 35S-20A7 or wild type 
Moneymaker plants (c) Example of foci reduction conferred by incubation with tomato-made 
IgA. Left: wild type “Juice”; right: transgenic “Juice”.  
Figure 6. Purple tomatoes anti-VP8*. (a) Tomato fruit, “powder” and  “juice” samples from 
WT (right) and Del/Ros1/IgH/IgL tomatoes (left); (b) Endpoint anti-VP8*  ELISA titering of 
purple and red tomato “powder”. Samples were obtained by pooling three fruits from each plant, 
namely a wild type plant (WT), the IgA-free control purple plant CR2-3-5 (Del/Ros1), the elite 
IgA-containing 35S-20A7 plant (IgA) and CR2-3-8 (IgA/Del/Ros1) respectively. Samples were 
titered in triplicates against VP8* or BSA (only CR2-3-8  line), with bars representing standard 
error. (c) Virus neutralization assay of purple IgA tomatoes. The IgA content in a “powder” 
sample consisting of three pooled fruits from the elite line CR2-3-8 was estimated by sandwich 
ELISA. “Powder” samples from CR2-3-8 and its Del/Ros1-positive, IgA-negative sibling line 
CR2-3-5 were reconstituted in PBS in equivalent dilution series and pre-incubated with 
rotavirus SA11 prior to infect MA104 cell monolayers. Samples were analyzed in triplicate and 
neutralization is represented as the mean percentage of the reduction of foci number with 
respect to the CR2-3-5 control line, with bars representing the standard error. 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
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FIGURE 5 
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FIGURE 6 
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